Basel, Switzerland
Matterhorn Biosciences, established in 2020, is pioneering a breakthrough in the biopharmaceutical sector with its focus on MR1 directed cell therapy. Positioned as a leader, the company leverages its proprietary M-TCR cell therapy platform to target the underlying mechanisms of cancer.
Operating out of Switzerland, this innovative firm functions at the intersection of the Biopharma, Biotechnology, and Health Care industries. Matterhorn's approach, encapsulated by its slogan — "M-TCR cell therapies targeting a new hallmark of cancer" — highlights its commitment to cutting-edge cancer treatment.
In August 2020, Matterhorn Biosciences secured a significant $30.00 million from a Venture Round led by Versant Ventures, underpinning its promising R&D endeavors. This investment marks a vote of confidence from seasoned investors, indicative of the substantial potential investors see in Matterhorn's transformative and targeted therapeutic solutions.
TC BioPharm
Inceptor Bio
